Hologic (HOLX)
(Delayed Data from NSDQ)
$76.71 USD
-0.48 (-0.62%)
Updated Apr 24, 2024 04:00 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Company Summary
Headquartered in Bedford, MA, Hologic Inc. develops, manufactures, and supplies diagnostics, medical imaging systems and surgical products which cater to the healthcare needs of women.
Hologic operates through the following four segments:
Diagnostics (46.6% of total revenues in FY23): With the Gen-Probe acquisition, Hologic currently offers APTIMA family of assays that includes the APTIMA Combo 2 assay, which feature the APTIMA CT and APTIMA GC assays, the APTIMA HPV assay and the APTIMA Trichomonas assay. Other products include the ThinPrep system, primarily used in cytology applications.
Company Summary
Headquartered in Bedford, MA, Hologic Inc. develops, manufactures, and supplies diagnostics, medical imaging systems and surgical products which cater to the healthcare needs of women.
Hologic operates through the following four segments:
Diagnostics (46.6% of total revenues in FY23): With the Gen-Probe acquisition, Hologic currently offers APTIMA family of assays that includes the APTIMA Combo 2 assay, which feature the APTIMA CT and APTIMA GC assays, the APTIMA HPV assay and the APTIMA Trichomonas assay. Other products include the ThinPrep system, primarily used in cytology applications.
Breast Health (35.5% of total revenues in FY23): Products include a broad portfolio of breast imaging and related products and accessories, including digital and film-based mammography systems, computer-aided detection (CAD), breast biopsy guidance systems, minimally invasive breast biopsy and tissue extraction devices and breast brachytherapy products.
GYN Surgical (14.9% of total revenues in FY23): Products include the NovaSure endometrial ablation system – used in the treatment of heavy menstrual bleeding and the MyoSure hysteroscopic tissue removal system – which allows incision less removal of fibroids and polyps within the uterus.
Skeletal Health (2.8% of total revenues in FY23): This segment includes dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and Fluoroscan mini-C arm imaging products.
General Information
Hologic, Inc
250 CAMPUS DRIVE
MARLBOROUGH, MA 01752
Phone: 508-263-2900
Fax: 781-890-8031
Email: ryan.simon@hologic.com
Industry | Medical - Instruments |
Sector | Medical |
Fiscal Year End | September |
Last Reported Quarter | 3/31/2024 |
Earnings Date | 5/2/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.97 |
Current Year EPS Consensus Estimate | 4.01 |
Estimated Long-Term EPS Growth Rate | 7.40 |
Earnings Date | 5/2/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 77.19 |
52 Week High | 87.88 |
52 Week Low | 64.02 |
Beta | 1.00 |
20 Day Moving Average | 1,497,904.00 |
Target Price Consensus | 84.36 |
4 Week | 1.34 |
12 Week | 3.02 |
YTD | 8.03 |
4 Week | 5.01 |
12 Week | 0.05 |
YTD | 1.55 |
Shares Outstanding (millions) | 234.73 |
Market Capitalization (millions) | 18,118.93 |
Short Ratio | NA |
Last Split Date | 4/3/2008 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 19.12 |
Trailing 12 Months | 19.87 |
PEG Ratio | 2.60 |
vs. Previous Year | -8.41% |
vs. Previous Quarter | 10.11% |
vs. Previous Year | -5.69% |
vs. Previous Quarter | 7.17% |
Price/Book | 3.87 |
Price/Cash Flow | 14.37 |
Price / Sales | 4.54 |
3/31/24 | NA |
12/31/23 | 18.91 |
9/30/23 | 19.12 |
3/31/24 | NA |
12/31/23 | 10.47 |
9/30/23 | 10.58 |
3/31/24 | NA |
12/31/23 | 3.89 |
9/30/23 | 3.47 |
3/31/24 | NA |
12/31/23 | 3.18 |
9/30/23 | 2.95 |
3/31/24 | NA |
12/31/23 | 24.00 |
9/30/23 | 24.42 |
3/31/24 | NA |
12/31/23 | 12.98 |
9/30/23 | 11.31 |
3/31/24 | NA |
12/31/23 | 15.83 |
9/30/23 | 16.77 |
3/31/24 | NA |
12/31/23 | 19.83 |
9/30/23 | 20.48 |
3/31/24 | NA |
12/31/23 | 2.98 |
9/30/23 | 2.94 |
3/31/24 | NA |
12/31/23 | 0.55 |
9/30/23 | 0.51 |
3/31/24 | NA |
12/31/23 | 35.28 |
9/30/23 | 33.67 |